Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
ApexOnco Front Page
Recent articles
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
ESMO and the Triple Meeting approach.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
Genmab acquires the Dutch biotech for $8bn.
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
BNT329 enters the clinic, as do four other new ADCs.
